Review: Aspirin reduces vascular events but increases bleeding in primary and secondary prevention

Mukherjee, Debabrata; Baigent, C.
September 2009
ACP Journal Club;9/22/2009, Vol. 151 Issue 3, p2
Academic Journal
The article presents the findings of a study regarding the benefits and risks of aspirin. Aspirin is stated to reduce vascular events but increases bleeding in primary and secondary prevention. Primary prevention trials included patients who did not have diabetes and were scheduled for 2 years of treatment. Secondary prevention trials included patients with previous myocardial infarction (MI), stroke or transient cerebral ischemia.


Related Articles

  • Aspirin use in primary prevention 'unjustified'. Moberly, Tom // GP: General Practitioner;6/5/2009, p15 

    The article discusses a study which suggests that aspirin should not be routinely used in the primary prevention of vascular events in Great Britain. It states that researchers from Oxford University implemented a meta-analysis of data from six primary prevention studies, which included 95,000...

  • Aspirin and dipyridamole for the secondary prevention of stroke. Zielinski, Rafal; French, Linda // Journal of Family Practice;Feb1999, Vol. 48 Issue 2, p92 

    The article cites a research study that investigates whether low-dose acetylsalicylic acid (ASA) or modified-release dipyridamole are efficacious in secondary prevention of ischemic stroke. The Second European Stroke Prevention Study (ESPS-2) was a randomized double-blind clinical trial of...

  • Review: dipyridamole given with or without aspirin reduces recurrent stroke. Leonardi-Bee, J.; Bath, P. M.; Bousser, M. G. // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p113 

    The article presents a study on the effectiveness of dipyridamole in reducing recurrent stroke. 5 RCTs were included in the intention to treat meta-analysis of individual patient data using a logistic regression model with random effects for trial and fixed effects for treatment assignment. Risk...

  • Review: dipyridamole given with or without aspirin reduces recurrent stroke: Commentary. Hankey, Graeme J. // Evidence Based Medicine;Aug2005, Vol. 10 Issue 4, p113 

    Presents the author's comments on the effectiveness of dipyridamole and aspirin in reducing recurrent stroke. Use of dipyridamole and aspirin as first line treatment for transient ischaemic attack (hA) and stroke; Benefits of aspirin; Role of aspirin in antiplatelet therapy for patients with hA...

  • Rivaroxaban being tested in patients with arrhythmia disorders in ROCKET AF trial.  // Cardiology Today;Nov2008, Vol. 11 Issue 11, p11 

    The article reports that the ROCKET AF clinical trial investigated the safety and efficacy of rivaroxaban compared to warfarin in treating patients with arrhythmia disorders in the U.S. The trial will involve at least 14,000 persons who will be randomly assigned to rivaroxaban or warfarin during...

  • Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atriai fibrillation. Connofly, S. J.; Pogue, J.; Hart, R.; Sloan, Michael A. // Evidence Based Medicine;Dec2006, Vol. 11 Issue 6, p170 

    The article cites that clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in patients with atrial fibrillation. Limitations of the study include the rates of stroke and other vascular events which were lower than in other trials. Some bias probably...

  • 'Wishful thinking' blamed for clinical trials flops. Dickinson, James G. // Medical Marketing & Media;Aug2011, Vol. 46 Issue 8, p10 

    The article focuses on the results of a research study which confirm the association of wishful thinking on the increasing failures of clinical trials due to lack of efficacy and strategic reasons in the U.S.

  • SPIRIT IV results reinforce Xience safety and efficacy.  // Medical Device Daily;5/7/2010, Vol. 14 Issue 88, p11 

    The article deals with the results from Abbott's SPIRIT IV trial, a randomized clinical trial comparing Abbott's Xience V Everolimus Eluting Coronary Stent System and the Taxus Express2 Paclitaxel-Eluting Coronary Stent System, pubished in a 2010 issue of the "New England Journal of Medicine."

  • Flare-Ups of Gout Reduced.  // Clarendon Enterprise (TX);10/2/2008, Vol. 19 Issue 39, p7 

    The article highlights the results of a clinical trial of Arcalyst (rilonacept), an inhibitor of interluekin-1, a body protein that drives inflammation in a number of conditions including gout.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics